CRA consultants supported a pharmaceutical company in its successful challenge of an ANDA filed by a generic manufacturer. The generic company sought to manufacture and sell generic versions of two related diabetes treatments. CRA provided a report analyzing evidence of commercial success for the branded pharmaceutical products as well as deposition and trial testimony.
Recent trends in Rule 702 decisions – 2024
In this CRA Insights, we update the Rule 702 decision trends in last year’s Insights with 2023 data.[1] We also provide descriptions of four specific...